2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. Insulin Receptor
  5. Insulin Receptor Antagonist

Insulin Receptor Antagonist

Insulin Receptor Antagonists (12):

Cat. No. Product Name Effect Purity
  • HY-P10138
    human GIP(3-30), amide
    		Antagonist 99.76%
    Human GIP(3-30), amide is a high affinity antagonist of the human GIP receptor in vitro. Human GIP(3-30), amide has potential anti-obesity and anti-diabetic effects.
  • HY-P2093B
    S961 acetate
    		Antagonist 99.98%
    S961 acetate is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.
  • HY-164535
    Maridebart cafraglutide
    		Antagonist 99.24%
    Maridebart cafraglutide (AMG 133) is a long-acting peptide-antibody conjugate that combines GLP-1 receptor agonist with glucose-dependent insulinotropic polypeptide (GIP) receptor antagonism. Maridebart cafraglutide shows antagonist activity against human, cynomolgus monkey and rat GIPR with IC50 values of 46.4 nM, 26.5 nM, 822.3 nM, respectively. Maridebart cafraglutide shows agonist activity against human, cynomolgus monkey, rat and mouse GLP-1R with EC50 values of 24.4 pM, 5.7 pM, 2.4 pM and 123 pM, respectively. Maridebart cafraglutide can be used for the study of obesity and type 2 diabetes.
  • HY-P2542
    GIP (3-42), human
    		Antagonist 99.75%
    GIP (3-42), human acts as a glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, moderating the insulin secreting and metabolic actions of GIP in vivo.
  • HY-P10138A
    human GIP(3-30), amide TFA
    		Antagonist
    Human GIP(3-30), amide TFA is the TFA salt form of human GIP(3-30), amide (HY-P10138). Human GIP(3-30), amide TFA is a high affinity antagonist of the human GIP receptor in vitro. Human GIP(3-30), amide TFA has potential anti-obesity and anti-diabetic effects.
  • HY-P2093
    S961
    		Antagonist 99.66%
    S961 is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.
  • HY-P1434
    [Pro3]-GIP (mouse)
    		Antagonist 98.84%
    [Pro3]-GIP (mouse) is a GIP receptor antagonist (IC50: 2.6 μM). [Pro3]-GIP (mouse) improves glucose tolerance and insulin sensitivity in ob/ob mice. [Pro3]-GIP (mouse) can be used for research of type 2 diabetes.
  • HY-W039923
    β-D-Galactose pentaacetate
    		Antagonist 99.61%
    β-D-Galactose pentaacetate is a negative regulator of insulin with plasma membrane penetrating ability and can be hydrolyzed by intracellular esterases. β-D-Galactose pentaacetate inhibits Leucine (HY-N0486)-induced insulin release in Wistar rat islets, potentially preventing excessive insulin release in pathological conditions.
  • HY-P991290
    IRAB-B
    		Antagonist 98.30%
    IRAB-B is a human monoclonal antibody targeting INSR. IRAB-B is an insulin receptor (IR) antagonist and can be used in the study of insulin resistance and diabetes.
  • HY-15481
    KU14R
    		Antagonist 98.91%
    KU14R is a new I(3)-R antagonist, which selectively blocks the insulin secretory response to imidazolines.
  • HY-P2093A
    S961 TFA
    		Antagonist
    S961 TFA is an high-affinity and selective insulin receptor (IR) antagonist with IC50s of 0.048, 0.027, and 630 nM for HIR-A, HIR-B, and human insulin-like growth factor I receptor (HIGF-IR) in SPA-assay, respectively.
  • HY-P991291
    XOMA 129
    		Antagonist
    XOMA 129 is a human monoclonal antibody targeting INSR. XOMA 129 is an insulin receptor (IR) antagonist that inhibits the drop in blood glucose. XOMA 129 can be used in the study of hypoglycemia .